Mohammad Ahsan Alamgir, MD
Hematology & Oncology · Charleston, WVNPI 1265609671
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by AstraZeneca at 46.3% of the total. 2025 is the largest year on record at $3,786, 5.2 times the $725 reported in 2019.
Across 81 payments — averaging $106.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Genentech USA, Inc.$1K
- Incyte Corporation$755
- Daiichi Sankyo Inc.$391
- E.r. Squibb & Sons, L.L.C.$310
- Merck$206
- plus $2K from 22 others
What the payments were for
- Consulting fees$4,19549%
- Food & beverage$4,00746%
- Education$4195%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $3,996 |
| Genentech USA, Inc. | 1 | $1,070 |
| Incyte Corporation | 7 | $755 |
| Daiichi Sankyo Inc. | 4 | $391 |
| E.r. Squibb & Sons, L.L.C. | 10 | $310 |
| Merck | 2 | $206 |
| AbbVie | 4 | $203 |
| Regeneron Healthcare Solutions, Inc. | 2 | $155 |
| Novartis | 8 | $148 |
| Gilead | 2 | $139 |
| Amgen | 2 | $137 |
| Tempus AI, Inc | 5 | $136 |
| Mirati Therapeutics, Inc. | 1 | $125 |
| Boston Scientific | 1 | $125 |
| Rigel Pharmaceuticals, Inc. | 1 | $125 |
| Verastem, Inc. | 1 | $124 |
| Lilly USA, LLC | 1 | $118 |
| Bristol Myers Squibb | 5 | $101 |
| Tersera Therapeutics LLC | 2 | $63 |
| Johnson & Johnson | 3 | $44 |
| Sanofi | 1 | $28 |
| Springworks Therapeutics, Inc. | 1 | $25 |
| Beigene USA, Inc. | 1 | $20 |
| Array Biopharma Inc | 1 | $19 |
| GSK | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Seagen Inc. | 1 | $15 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,622 in reported general payments places this provider in the 80th percentile of 72 hematology & oncology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 51 | $575,239 |
| VenclextaVenetoclax | 31 | $399,623 |
| XtandiEnzalutamide | 24 | $322,446 |
| BrukinsaZanubrutinib | 18 | $257,941 |
| IbrancePalbociclib | 15 | $226,391 |
| TibsovoIvosidenib | 12 | $199,929 |
| RevlimidLenalidomide | 13 | $182,736 |
| EliquisApixaban | 47 | $28,703 |
| Imatinib Mesylate | 15 | $7,746 |
| Xtampza ErOxycodone Myristate | 11 | $6,887 |
| XareltoRivaroxaban | 11 | $6,022 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $1,851 |
| Anastrozole | 81 | $1,803 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 48 | $1,240 |
| Letrozole | 107 | $1,215 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVenclexta | $203 | $399,62331 claims |
| Beigene USA, Inc.Brukinsa | $20 | $257,94118 claims |
| Bristol Myers SquibbRevlimid | $101 | $182,73613 claims |
| Johnson & JohnsonXarelto | $44 | $6,02211 claims |
| Lilly USA, LLCOlanzapine | $118 | $15319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 72 hematology & oncology providers in West Virginia.
Other hematology & oncology in Charleston
- Pranali PachikaCharleston$9K
- Nagabhishek MokaCharleston$8K
- Ahmed KhalidCharleston$8K
- Moussa SissokoCharleston$5K
- Kok Hoe ChanCharleston$2K
- Muhammad AwidiCharleston$559
- Chitta SarkerCharleston$304
- Steven JubelirerCharleston$253
- Damian SilberminsHuntington$277K
- Abraham KanateMorgantown$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.